Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model

British Journal of Haematology

Volumn 167, Issue 5, 2014, Pages 651-663

  Nur, Haneen ^a,b   Rao, Luigia ^c   Frassanito, Maria Antonia ^c   De Raeve, Hendrik ^d   Ribatti, Domenico ^c,e   Mfopou, Josué Kunjom ^a   Van Valckenborgh, Els ^a   De Bruyne, Elke ^a   Vacca, Angelo ^c   Vanderkerken, Karin ^a   Menu, Eline ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b HEBRON UNIVERSITY   (Palestine)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Invariant natural killer T cells; JAK STAT pathway; MM induced angiogenesis; Multiple myeloma; Galactosylceramide

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; JANUS KINASE; STAT PROTEIN; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MIGRATION INHIBITION; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR VASCULARIZATION; ANIMAL; CELL LINE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; GALACTOSYLCERAMIDES; IMMUNOTHERAPY; INTERFERON-GAMMA; JANUS KINASES; MICE; MULTIPLE MYELOMA; NATURAL KILLER T-CELLS; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84925226399     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13092     Document Type: Article

References (79)

1. Angiolillo, A.L., Sgadari, C., Taub, D.D., Liao, F., Farber, J.M., Maheshwari, S., Kleinman, H.K., Reaman, G.H. & Tosato, G. (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. The Journal of Experimental Medicine, 182, 155-162.
2. Aoudjit, F., Potworowski, E.F. & St-Pierre, Y. (1998) Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. Journal of Immunology, 160, 2967-2973.
3. Arenberg, D.A., Kunkel, S.L., Polverini, P.J., Morris, S.B., Burdick, M.D., Glass, M.C., Taub, D.T., Iannettoni, M.D., Whyte, R.I. & Strieter, R.M. (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. The Journal of Experimental Medicine, 184, 981-992.
4. Bhutani, M., Turkbey, B., Tan, E., Kemp, T.J., Pinto, L.A., Berg, A.R., Korde, N., Minter, A.R., Weiss, B.M., Mena, E., Lindenberg, L., Aras, O., Purdue, M.P., Hofmann, J.N., Steinberg, S.M., Calvo, K.R., Choyke, P.L., Maric, I., Kurdziel, K. & Landgren, O. (2014) Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia, 28, 413-416.
5. Brennan, P.J., Brigl, M. & Brenner, M.B. (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nature Reviews Immunology, 13, 101-117.
6. Campanella, G.S., Colvin, R.A. & Luster, A.D. (2010) CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One, 5, e12700.
7. Cao, R., Farnebo, J., Kurimoto, M. & Cao, Y. (1999) Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB Journal, 13, 2195-2202.
8. Cerundolo, V., Silk, J.D., Masri, S.H. & Salio, M. (2009) Harnessing invariant NKT cells in vaccination strategies. Nature Reviews Immunology, 9, 28-38.
9. Chanan-Khan, A.A., Swaika, A., Paulus, A., Kumar, S.K., Mikhael, J.R., Rajkumar, S.V., Dispenzieri, A. & Lacy, M.Q. (2013) Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer journal, 3, e143.
10. Chang, D.H., Osman, K., Connolly, J., Kukreja, A., Krasovsky, J., Pack, M., Hutchinson, A., Geller, M., Liu, N., Annable, R., Shay, J., Kirchhoff, K., Nishi, N., Ando, Y., Hayashi, K., Hassoun, H., Steinman, R.M. & Dhodapkar, M.V. (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. The Journal of Experimental Medicine, 201, 1503-1517.
11. Chang, D.H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S.D., Jagannath, S. & Dhodapkar, M.V. (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood, 108, 618-621.
12. Chin, Y.E., Kitagawa, M., Kuida, K., Flavell, R.A. & Fu, X.Y. (1997) Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Molecular and Cellular Biology, 17, 5328-5337.
13. Coughlin, C.M., Salhany, K.E., Gee, M.S., LaTemple, D.C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J.E., Liu, L., Liao, F., Farber, J.M., Pestka, S., Trinchieri, G. & Lee, W.M. (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity, 9, 25-34.
14. Daly, M.E., Makris, A., Reed, M. & Lewis, C.E. (2003) Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? Journal of the National Cancer Institute, 95, 1660-1673.
15. Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210-216.
16. De Keersmaecker, B., Allard, S.D., Lacor, P., Schots, R., Thielemans, K. & Aerts, J.L. (2012) Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. Journal of Virology, 86, 9351-9360.
17. De Luisi, A., Ferrucci, A., Coluccia, A.M., Ria, R., Moschetta, M., de Luca, E., Pieroni, L., Maffia, M., Urbani, A., Di Pietro, G., Guarini, A., Ranieri, G., Ditonno, P., Berardi, S., Caivano, A., Basile, A., Cascavilla, N., Capalbo, S., Quarta, G., Dammacco, F., Ribatti, D. & Vacca, A. (2011) Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clinical Cancer Research, 17, 1935-1946.
18. Dhodapkar, M.V., Geller, M.D., Chang, D.H., Shimizu, K., Fujii, S., Dhodapkar, K.M. & Krasovsky, J. (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. The Journal of Experimental Medicine, 197, 1667-1676.
19. Fang, X., Du, P., Liu, Y. & Tang, J. (2010) Efficient isolation of mouse liver NKT cells by perfusion. PLoS One, 5, e10288.
20. Feldman, A.L., Friedl, J., Lans, T.E., Libutti, S.K., Lorang, D., Miller, M.S., Turner, E.M., Hewitt, S.M. & Alexander, H.R. (2002) Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. International Journal of Cancer Journal International du Cancer, 99, 149-153.
21. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine, 285, 1182-1186.
22. Galustian, C., Meyer, B., Labarthe, M.C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., Schafer, P., Bartlett, J.B. & Dalgleish, A.G. (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy: CII, 58, 1033-1045.
23. Giles, F.J. (2002) The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology, 16, 23-29.
24. Grepin, R. & Pages, G. (2010) Molecular mechanisms of resistance to tumour anti-angiogenic strategies. Journal of Oncology, 2010, 835680.
25. Hahne, M., Jager, U., Isenmann, S., Hallmann, R. & Vestweber, D. (1993) Five tumor necrosis factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes. The Journal of Cell Biology, 121, 655-664.
26. Hanahan, D. & Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
27. Hayakawa, Y., Takeda, K., Yagita, H., Kakuta, S., Iwakura, Y., Van Kaer, L., Saiki, I. & Okumura, K. (2001) Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. European Journal of Immunology, 31, 1720-1727.
28. Hayakawa, Y., Takeda, K., Yagita, H., Smyth, M.J., Van Kaer, L., Okumura, K. & Saiki, I. (2002) IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood, 100, 1728-1733.
29. Hong, S., Lee, H., Jung, K., Lee, S.M., Lee, S.J., Jun, H.J., Kim, Y., Song, H., Bogen, B. & Choi, I. (2013) Tumor cells loaded with alpha-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma. Immunology Letters, 156, 132-139.
30. Ikeda, H., Old, L.J. & Schreiber, R.D. (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine & Growth Factor Reviews, 13, 95-109.
31. Imai, K., Kobayashi, M., Wang, J., Ohiro, Y., Hamada, J., Cho, Y., Imamura, M., Musashi, M., Kondo, T., Hosokawa, M. & Asaka, M. (1999) Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells. Blood, 93, 149-156.
32. Jakob, C., Sterz, J., Zavrski, I., Heider, U., Kleeberg, L., Fleissner, C., Kaiser, M. & Sezer, O. (2006) Angiogenesis in multiple myeloma. European Journal of Cancer, 42, 1581-1590.
33. Kerr, I.M., Costa-Pereira, A.P., Lillemeier, B.F. & Strobl, B. (2003) Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Letters, 546, 1-5.
34. Kikuchi, A., Nieda, M., Schmidt, C., Koezuka, Y., Ishihara, S., Ishikawa, Y., Tadokoro, K., Durrant, S., Boyd, A., Juji, T. & Nicol, A. (2001) In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. British Journal of Cancer, 85, 741-746.
35. Kumar, V. & Delovitch, T.L. (2014) Different subsets of natural killer T cells may vary in their roles in health and disease. Immunology, 142, 321-336.
36. Li, J.H., Kluger, M.S., Madge, L.A., Zheng, L., Bothwell, A.L. & Pober, J.S. (2002) Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis. The American Journal of Pathology, 161, 1485-1495.
37. Lu, L., Payvandi, F., Wu, L., Zhang, L.H., Hariri, R.J., Man, H.W., Chen, R.S., Muller, G.W., Hughes, C.C., Stirling, D.I., Schafer, P.H. & Bartlett, J.B. (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvascular Research, 77, 78-86.
38. Macho-Fernandez, E., Cruz, L.J., Ghinnagow, R., Fontaine, J., Bialecki, E., Frisch, B., Trottein, F. & Faveeuw, C. (2014) Targeted delivery of alpha-galactosylceramide to CD8alpha+ dendritic cells optimizes type I NKT cell-based antitumor responses. Journal of Immunology, 193, 961-969.
39. Marriott, J.B., Clarke, I.A., Dredge, K., Muller, G., Stirling, D. & Dalgleish, A.G. (2002) Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clinical and Experimental Immunology, 130, 75-84.
40. Matsuda, J.L., Mallevaey, T., Scott-Browne, J. & Gapin, L. (2008) CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Current Opinion in Immunology, 20, 358-368.
41. Mattarollo, S.R., West, A.C., Steegh, K., Duret, H., Paget, C., Martin, B., Matthews, G.M., Shortt, J., Chesi, M., Bergsagel, P.L., Bots, M., Zuber, J., Lowe, S.W., Johnstone, R.W. & Smyth, M.J. (2012) NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood, 120, 3019-3029.
42. Mayo, J.N., Chen, C.H., Liao, F.F. & Bearden, S.E. (2014) Homocysteine disrupts outgrowth of microvascular endothelium by an iNOS-dependent mechanism. Microcirculation, 21, 541-550.
43. Medinger, M. & Mross, K. (2010) Clinical trials with anti-angiogenic agents in hematological malignancies. Journal of Angiogenesis Research, 2, 10.
44. Menu, E., Kooijman, R., Van Valckenborgh, E., Asosingh, K., Bakkus, M., Van Camp, B. & Vanderkerken, K. (2004) Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. British Journal of Cancer, 90, 1076-1083.
45. Menu, E., De Leenheer, E., De Raeve, H., Coulton, L., Imanishi, T., Miyashita, K., Van Valckenborgh, E., Van Riet, I., Van Camp, B., Horuk, R., Croucher, P. & Vanderkerken, K. (2006) Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clinical & Experimental Metastasis, 23, 291-300.
46. Mitsiades, C.S. & Chen-Kiang, S. (2013) Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Critical Reviews in Oncology/Hematology, 88, S5-S13.
47. Moehler, T.M., Hillengass, J., Goldschmidt, H. & Ho, A.D. (2004) Antiangiogenic therapy in hematologic malignancies. Current Pharmaceutical Design, 10, 1221-1234.
48. Nakagawa, K., Iwabuchi, K., Ogasawara, K., Ato, M., Kajiwara, M., Nishihori, H., Iwabuchi, C., Ishikura, H., Good, R.A. & Onoe, K. (1997) Generation of NK1.1+ T cell antigen receptor alpha/beta+ thymocytes associated with intact thymic structure. Proceedings of the National Academy of Sciences of the United States of America, 94, 2472-2477.
49. Nastala, C.L., Edington, H.D., McKinney, T.G., Tahara, H., Nalesnik, M.A., Brunda, M.J., Gately, M.K., Wolf, S.F., Schreiber, R.D., Storkus, W.J. & Lotze, M.T. (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. Journal of Immunology, 153, 1697-1706.
50. Neparidze, N. & Dhodapkar, M.V. (2009) Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Annals of the New York Academy of Sciences, 1174, 61-67.
51. Nur, H., Elewaut, D., Vanderkerken, K. & Menu, E. (2013a) The Role of Invariant Natural Killer T cells in Cancer. International Blood Research & Reviews, 1, 44-71.
52. Nur, H., Fostier, K., Aspeslagh, S., Renmans, W., Bertrand, E., Leleu, X., Favreau, M., Breckpot, K., Schots, R., De Waele, M., Van Valckenborgh, E., De Bruyne, E., Facon, T., Elewaut, D., Vanderkerken, K. & Menu, E. (2013b) Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. PLoS One, 8, e65075.
53. Quach, H., Ritchie, D., Stewart, A.K., Neeson, P., Harrison, S., Smyth, M.J. & Prince, H.M. (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 24, 22-32.
54. Radl, J., De Glopper, E.D., Schuit, H.R. & Zurcher, C. (1979) Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. Journal of Immunology, 122, 609-613.
55. Rajkumar, S.V., Leong, T., Roche, P.C., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Kyle, R.A., Gertz, M.A. & Greipp, P.R. (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clinical Cancer Research, 6, 3111-3116.
56. Rawlings, J.S., Rosler, K.M. & Harrison, D.A. (2004) The JAK/STAT signaling pathway. Journal of Cell Science, 117, 1281-1283.
57. Ria, R., Reale, A., De Luisi, A., Ferrucci, A., Moschetta, M. & Vacca, A. (2011) Bone marrow angiogenesis and progression in multiple myeloma. American Journal of Blood Research, 1, 76-89.
58. Ribatti, D., Nico, B., Pezzolo, A., Vacca, A., Meazza, R., Cinti, R., Carlini, B., Parodi, F., Pistoia, V. & Corrias, M.V. (2006) Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-gamma. British Journal of Cancer, 94, 1845-1852.
59. Richter, J., Neparidze, N., Zhang, L., Nair, S., Monesmith, T., Sundaram, R., Miesowicz, F., Dhodapkar, K.M. & Dhodapkar, M.V. (2013) Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood, 121, 423-430.
60. Roccaro, A.M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P.G. & Anderson, K.C. (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research, 66, 184-191.
61. Saha, B., Jyothi Prasanna, S., Chandrasekar, B. & Nandi, D. (2010) Gene modulation and immunoregulatory roles of interferon gamma. Cytokine, 50, 1-14.
62. Schindler, C., Levy, D.E. & Decker, T. (2007) JAK-STAT signaling: from interferons to cytokines. The Journal of Biological Chemistry, 282, 20059-20063.
63. Schroder, K., Hertzog, P.J., Ravasi, T. & Hume, D.A. (2004) Interferon-gamma: an overview of signals, mechanisms and functions. Journal of Leukocyte Biology, 75, 163-189.
64. Sgadari, C., Angiolillo, A.L. & Tosato, G. (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood, 87, 3877-3882.
65. Song, W., van der Vliet, H.J., Tai, Y.T., Prabhala, R., Wang, R., Podar, K., Catley, L., Shammas, M.A., Anderson, K.C., Balk, S.P., Exley, M.A. & Munshi, N.C. (2008) Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clinical Cancer Research, 14, 6955-6962.
66. Spanoudakis, E., Hu, M., Naresh, K., Terpos, E., Melo, V., Reid, A., Kotsianidis, I., Abdalla, S., Rahemtulla, A. & Karadimitris, A. (2009) Regulation of multiple myeloma survival and progression by CD1d. Blood, 113, 2498-2507.
67. Strasly, M., Cavallo, F., Geuna, M., Mitola, S., Colombo, M.P., Forni, G. & Bussolino, F. (2001) IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. Journal of Immunology, 166, 3890-3899.
68. Tandle, A., Blazer, D.G. 3rd & Libutti, S.K. (2004) Antiangiogenic gene therapy of cancer: recent developments. Journal of Translational Medicine, 2, 22.
69. UKCCCR (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). British Journal of Cancer, 77, 1-10.
70. Vacca, A. & Ribatti, D. (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia, 20, 193-199.
71. Vacca, A., Ribatti, D., Roccaro, A.M., Frigeri, A. & Dammacco, F. (2001) Bone marrow angiogenesis in patients with active multiple myeloma. Seminars in Oncology, 28, 543-550.
72. Van Kaer, L. (2005) alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nature Reviews Immunology, 5, 31-42.
73. Van Kaer, L. (2007) NKT cells: T lymphocytes with innate effector functions. Current Opinion in Immunology, 19, 354-364.
74. Van Valckenborgh, E., De Raeve, H., Devy, L., Blacher, S., Munaut, C., Noel, A., Van Marck, E., Van Riet, I., Van Camp, B. & Vanderkerken, K. (2002) Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. British Journal of Cancer, 86, 796-802.
75. Vanderkerken, K., Asosingh, K., Croucher, P. & Van Camp, B. (2003) Multiple myeloma biology: lessons from the 5TMM models. Immunological Reviews, 194, 196-206.
76. Vanderkerken, K., Asosingh, K., Willems, A., De Raeve, H., Couck, P., Gorus, F., Croucher, P. & Van Camp, B. (2005) The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods in Molecular Medicine, 113, 191-205.
77. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. (2012) Targeting natural killer cells and natural killer T cells in cancer. Nature Reviews Immunology, 12, 239-252.
78. Voest, E.E., Kenyon, B.M., O'Reilly, M.S., Truitt, G., D'Amato, R.J. & Folkman, J. (1995) Inhibition of angiogenesis in vivo by interleukin 12. Journal of the National Cancer Institute, 87, 581-586.
79. Yang, J. & Richmond, A. (2004) The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Molecular Therapy, 9, 846-855.